E
EpimAb Biotherapeutics
Developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology
About EpimAb Biotherapeutics
EpimAb is a biopharmaceutical startup that operates in the oncology sector, developing innovative cancer treatments. The company has a robust and sustainable product pipeline, with four clinical projects and over ten pre-clinical candidate drugs. EpimAb's proprietary FIT-Ig® platform allows the company to precisely target three strategic oncology areas: tumor targeting, dual immune checkpoint, and immune cell guidance. This means they develop drugs that can target specific cancer cells, check the immune system's response, and guide immune cells to the tumor.
One of their key products, EMB-01, is a novel bispecific antibody, a type of drug that can bind to two different proteins at the same time. EMB-01 targets EGFR and cMet on tumor cells, which are proteins that can promote cancer growth. This drug is currently in Phase I/II clinical trials for non-small cell lung cancer (NSCLC) and several gastrointestinal (GI) cancers in the U.S. and China.
Another product, EMB-06, is a recombinant humanized bispecific antibody that targets B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) on tumor cells. This drug can recruit and activate T lymphocytes, a type of white blood cell, to kill tumor cells. It is currently in a global Phase I/II study in Australia and China for multiple myeloma, a type of blood cancer.
EpimAb's business model revolves around the research, development, and commercialization of these innovative cancer treatments. The company makes money by progressing these drugs through clinical trials and eventually selling them to healthcare providers and patients.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2021 | $120M | $480M | Mirae Asset Capital · China Merchants Bank · Cormorant Asset Management · ShangBay Capital | — |
| SERIES BOther financing | Jun 2019 | $74M | $296M | Sherpa Venture Partners · SDIC Fund Management | — |
Growth signals
Latest recorded traffic for EpimAb Biotherapeutics is 1.8K monthly website visits, up 592.3% over the last three months. EpimAb Biotherapeutics's team declined 5.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EpimAb Biotherapeutics in the Pudong ecosystem
The EpimAb Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Decheng Capital
3E Bioventures
Sherpa Venture Partners
SDIC Fund Management
Series B and later11 investors entered at this stage
CMB International Capital
Mirae Asset Capital
China Merchants Bank
Cormorant Asset Management
ShangBay Capital
State Development & Investment Corporation (SDIC)
Yanchuang Capital
Hidragon Capital- HCHony Capital
Octagon Capital Partners
Adrian Cheng
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EpimAb Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EpimAb Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








